Home » Alexion Faces Potential $25 Million Charge From Recall
Alexion Faces Potential $25 Million Charge From Recall
Alexion’s recall and replacement of vials of its rare disease drug Soliris could cost the company between $10 and $25 million in the fourth quarter, the drugmaker says in a recent SEC filing. The recall and replacement was prompted by the presence of visible particles observed as part of Alexion’s periodic testing of retained samples.
Drug GMP Report
Drugs Postmarket Safety Regulatory AffairsDrug GMP Report
Upcoming Events
-
18Jul
-
21Oct